Prostaglandin F2α synthase promotes oxaliplatin resistance in colorectal cancer through prostaglandin F2α-dependent and F2α-independent mechanism

Table 1 Correlation between prostaglandin F_2α synthase expression level and clinicopathological characteristics in 37 colorectal cancer patients, n (%)

Variables	No. of patients	Relatives PGFS expressions (mean ± SD)	P value
All cases	37 (100)
Gender			0.376
Male	22 (59)	1.84 ± 1.67
Female	15 (41)	1.68 ± 1.02
Age (yr)			0.495
≥ 60	19 (51)	1.40 ± 0.8
< 60	18 (49)	2.12 ± 1.8
Tumor location			0.066
Colon	15 (41)	1.71 ± 1.2
Rectum	22 (59)	1.84 ± 1.65
Differentiations			0.437
Well and Moderately	26 (70)	1.65 ± 1.29
Poorly	11 (30)	1.81 ± 1.08
T stage			0.023a
T1 or T2	25 (68)	1.26 ± 0.52
T3 or T4	12 (32)	2.47 ± 0.87
Lymph node metastasis			0.063
No	25 (68)	1.17 ± 0.56
Yes	12 (32)	2.09 ± 1.69
AJCC stage			0.069
I or II	29 (78)	1.44 ± 0.89
III or IV	8 (22)	3.09 ± 2.69

^aP < 0.05 concluded that T stage was correlated with prostaglandin F2α synthase expression level. PGFS: Prostaglandin F_2α synthase; AJCC: American Joint Committee on Cancer.